Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the ona domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/risezcom/public_html/cord-blood.org.uk/wp-includes/functions.php on line 6170
Umbilical Cord Stem Cells for Treating Severe COVID-19 Patients - Cord Blood

Cord Blood

and Stem Cell Banking

Umbilical Cord Stem Cells for Treating Severe COVID-19 Patients

illustration of stem cells

The COVID-19 pandemic has led to an urgent need for effective treatments. Severe cases of the disease can lead to acute respiratory distress syndrome (ARDS) and multiple organ failure. The severity of the disease is determined by the inflammatory response in the body, rather than the viral load. This inflammatory response, known as the “cytokine storm,” can cause organ failure.

Mesenchymal stem cells (MSCs) have shown promise in reducing mortality and promoting recovery in severe COVID-19 patients. MSCs have anti-inflammatory and immunomodulatory properties that can benefit COVID-19 patients. They can be easily obtained from umbilical cord tissue and require less sophisticated equipment for processing.

Results:

A study was conducted in Indonesia to investigate the safety and effectiveness of umbilical cord MSCs as an additional treatment for severe COVID-19 patients.

  • Recruitment: 42 eligible subjects were randomly divided into two groups – the intervention group and the placebo control group.
  • General subject characteristics: There were no significant differences in baseline characteristics between the two groups.
  • Duration of hospitalization: There was no significant difference in the length of hospital stay between the two groups.
  • Brixia scores: The intervention group showed improvement in Brixia scores on days 15 and 22 compared to the control group.
  • Dyspnoea scores: Both groups showed improvement in dyspnoea scores on days 15 and 22, with no significant difference between the groups.
  • Oxygenation index: The intervention group showed significant improvement in the oxygenation index compared to the control group.
  • PCT, ESR, and CRP levels: There was no significant difference in these inflammatory markers between the two groups. However, the intervention group had a smaller increase in PCT values on day 22 compared to the control group.
  • Mortality: 16.7% of patients in both the intervention and control groups died during the study.

Conclusion:

This study suggests that umbilical cord MSCs may provide some benefits as an additional treatment for severe COVID-19 patients. However, more research is needed to fully understand the effectiveness and safety of this treatment approach.